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Introduction  
Gastroesophageal reflux disease (GERD) typically presents 
with heartburn and acid regurgitation, afflicting an estimated 18-
28% of the North American population.1 In 5-15% of chronic 
GERD, esophageal mucosa can transform from normal squamous 
to columnar mucosa with intestinal characteristics (intestinal meta-
plasia or Barrett’s esophagus [BE]).2-4 BE confers an estimated 
10-fold increase in risk for esophageal adenocarcinoma (EAC) 
above the general population, prompting screening and surveillance 
protocols. Time trends demonstrate that the incidence of EAC has 
continued to escalate in comparison to other cancers (colon, lung, 
and breast), and that the rising incidence cannot be explained on the 
basis of increased identification of previously undiagnosed EAC.5
Gastroenterology societies across the globe have published BE 
screening recommendations (Table).6-12 However, these recommen-
dations are not always based on high-quality evidence.13 In fact, a 
systematic analysis and critical appraisal of 8 BE practice guidelines 
published between 2005 and 2013 found that the majority of guide-
lines failed to meet the Appraisal of Guidelines for Research and 
Evaluation II (AGREE II) domains and most recommendations 
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In predisposed individuals with long standing gastroesophageal reflux disease (GERD), esophageal squamous mucosa can transform 
into columnar mucosa with intestinal metaplasia, commonly called Barrett’s esophagus (BE). Barrett’s mucosa can develop dysplasia, 
which can be a precursor for esophageal adenocarcinoma (EAC). However, most EAC cases are identified when esophageal symptoms 
develop, without prior BE or GERD diagnoses. While several gastrointestinal societies have published BE screening guidelines, these 
vary, and many recommendations are not based on high quality evidence. These guidelines are concordant in recommending targeted 
screening of predisposed individuals (eg, long standing GERD symptoms with age > 50 years, male sex, Caucasian race, obesity, and 
family history of BE or EAC), and against population based screening, or screening of GERD patients without risk factors. Targeted 
endoscopic screening programs provide earlier diagnosis of high grade dysplasia and EAC, and offer potential for endoscopic therapy, 
which can improve prognosis and outcome. On the other hand, endoscopic screening of the general population, unselected GERD 
patients, patients with significant comorbidities or patients with limited life expectancy is not cost-effective. New screening modalities, 
some of which do not require endoscopy, have the potential to reduce costs and expand access to screening for BE.
(J Neurogastroenterol Motil 2019;25:181-188)
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were level B (49%) or C (45%) quality evidence.14 Notably, 40% of 
EAC cases have no prolonged reflux history,15 and < 5% carry a 
prior diagnosis of BE.16 Within this context, this review addresses 
the balance between the clinical value and cost-effectiveness of BE 
screening.17
Clinical Value of Screening  
In predisposed individuals, BE progresses through low-grade 
dysplasia (LGD) and high-grade dysplasia (HGD) to EAC. 
Supporting this concept, the annual risk of progression to EAC 
is higher in HGD (6.0-7.0%)18,19 compared to community LGD 
diagnoses (0.4-0.6%)20,21 or non-dysplastic BE (0.1-0.3%, which 
has decreased in recent decades from previous higher estimated 
ranges).22-27 
Data suggest superior survival outcomes when EAC is diag-
nosed in pre-existing BE. In a study based on Surveillance, Epi-
demiology, and End Results and linked Medicare data, patients 
diagnosed with EAC in the setting of pre-existing BE had overall 
lower stage EAC and superior overall survival compared to those 
diagnosed with EAC without pre-existing BE (hazard ratio, 0.56; 
95% CI, 0.50-0.61 that persisted in an adjusted model with hazard 
ratio, 0.72; 95% CI, 0.65-0.80).28 Likewise, meta-analysis also 
demonstrated a survival advantage for EAC detected from screen-
ing protocols compared to symptom-based EAC diagnosis (relative 
risk of mortality, 0.73; 95% CI, 0.57-0.94), associated with earlier-
stage EAC diagnosis.29 
However, adjustment for lead- and length-time biases in these 
studies substantially attenuated these reported survival benefits. 
Nonetheless, data from a large Veterans Affairs cohort (> 8500 
cases of EAC) suggests that the observed survival benefit in EAC 
in the setting of pre-existing BE (hazard ratio, 0.69; 95% CI, 0.61-
0.80) stems largely from the earlier stage of EAC at diagnosis, find-
ing no evidence for lead-time or length-time biases in their find-
ings.30 Another report demonstrates that when symptoms prompt 
advanced EAC diagnosis without prior knowledge of BE, 5-year 
survival is abysmal (< 3%), while early EAC has a better prognosis 
(> 20% 5-year survival).31 
Consequently, screening can identify dysplastic BE or early 
EAC––when endoscopic ablative therapies could reduce mortality 
and prolong life while remaining cost-effective.6,32-36 When applied 
to dysplastic BE, radiofrequency ablation (RFA), photodynamic 
therapy, and endoscopic mucosal resection reduce progression to 
EAC.36-38 For example, in a multicenter sham-controlled trial of 
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lower with RFA treatment (1.2% vs 9.3%, P = 0.045).37 Thus, BE 
screening programs have the potential to impact the natural history 
of BE in select settings.
On meta-analysis, long-standing GERD symptoms increase 
the risk of long-segment BE 5-fold,39 yet BE is associated with 
esophageal hyposensitivity despite high reflux burden.40,41 Thus, 
heartburn symptoms diminish as BE develops, and focusing solely 
on heartburn may miss these hyposensitive patients. Supporting 
this concept, BE is reported in asymptomatic individuals, with a 
prevalence of 1.3-1.6% in European population studies,42,43 and 
5.6-6.8% in United States populations.2,44 The frequency of identi-
fication of BE was similar between patients with heartburn (8.3%) 
and without heartburn (5.6%, P = 0.1) among 1000 patients 
enrolled from a screening colonoscopy cohort, although the likeli-
hood of long-segment BE was higher when heartburn was present 
(2.6% vs 0.36%, P = 0.01).2 Further, GERD can present with 
atypical symptoms (chest pain, cough, sore throat, and laryngitis) 
or regurgitation without heartburn, and acid suppressive therapy 
can modify or resolve symptoms; BE and EAC are identified in 
these patients as well.45,46 Consequently, if heartburn were the sole 
symptom prompting screening, BE in atypical GERD, hyposensi-
tive, or asymptomatic populations would likely be missed. For a 
BE screening program to be successful, all individuals with risk 
factors in the setting of documented evidence of GERD (“proven 
GERD,” includes erosive esophagitis, biopsy-proven intestinal 
metaplasia, abnormal pH study, and peptic strictures)47 may need to 
be targeted, regardless of presenting symptoms. However, screen-
ing of the general population and of low-risk groups is clearly not 
cost-effective and not recommended (Table).
Costs of Screening  
Beyond the relatively rare but real medical risks associated with 
endoscopy and endoscopic therapies, the resources utilized for BE 
screening and therapy are tremendous. In a study conducted among 
the West Virginia Medicaid population in the late 1990s, limited 
by its prevalence-based approach prior to the widespread use of 
endoscopic ablative therapies, and exclusion of Medicare-eligible 
recipients, BE patients incurred 21.2% higher costs than GERD 
patients and 62.4% higher costs than the general Medicaid popula-
tion.48 In this study, the authors estimated that about two-thirds of 
the total medical costs in this population stemmed from pharmacy 
costs. Another cost analysis performed at the Durham Veterans 
Affairs Medical Center in North Carolina prior to the widespread 
use of ablative approaches suggested that the annual cost of outpa-
tient care for BE approximated United States dollar ($) 1241, with 
medications accounting for over half of total costs.49 The authors 
found that these monthly medication costs among patients with 
BE approximated those for patients with insulin-requiring diabetes 
mellitus in patients at this medical center. However, endoscopic 
ablative BE therapies carry risks as well as the need for more fre-
quent endoscopies, incurring higher resource utilization compared 
to GERD without BE.48,49 A European study, which included 6000 
GERD patients from Germany, Austria, and Switzerland, found 
that a diagnosis of BE resulted in more than double the yearly di-
rect medical costs compared to those with non-erosive reflux disease 
(Euros 631 vs 270), again driven primarily by increased medication 
costs.50
The highest-quality cost estimates of BE screening for GERD 
patients fall within a range of $10K-$25K per life-year saved, com-
paring favorably in cost-effectiveness with other accepted cancer 
screening strategies.51-55 These estimates are limited in methodol-
ogy, as there is a paucity of randomized trial evidence to accurately 
develop cost estimates, and most available studies are limited by 
lack of consideration of newer endoscopic ablative techniques, such 
as RFA.56 Incorporating endoscopic therapy for dysplasia and 
intramucosal EAC, this estimate shifts to around $22K,55 demon-
strating how dysplasia found on BE screening can prompt endo-
scopic ablative therapies, further improving cost-effectiveness over 
continued surveillance or esophagectomy.36,57-59 In contrast, per-
forming upper endoscopy for upper gastrointestinal cancer screen-
ing in the general population at the time of screening colonoscopy 
costs $116K per quality-adjusted life-year when compared with no 
screening––significantly higher than targeted screening, despite the 
reduced costs of performance at the time of colonoscopy.60
Limitations of Screening  
Endoscopic screening for BE has shortcomings. Adherence to 
screening recommendations is suboptimal; only 35% of practitio-
ners reported screening all chronic GERD patients with endoscopy 
in one survey.61,62 EAC is predominantly diagnosed without prior 
GERD or BE,16 and the majority with BE derive limited benefit 
from surveillance directed by findings on screening.63,64 Nationwide 
population-based work from Denmark suggests that the absolute 
annual risk of EAC among BE is 0.12%, lower than previously 
suspected.23 Moreover, work from the UK indicates that among 
BE, only 1.9% will die of esophageal cancer within 10 years; the 
remainder succumb more frequently to other diseases, such as isch-
emic coronary disease.63 
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The yield of endoscopic screening improves when adequate 
time is spent inspecting the esophagus and the identified BE seg-
ments, which increases detection of HGD and EAC.65 There is 
inter-observer variation in the histopathologic diagnosis of dysplasia 
in BE, particularly LGD, necessitating further biopsy review by ex-
pert pathologists before confirmation of dysplasia.66 Going forward, 
alternative or adjunctive screening tools under development (such 
as transnasal endoscopy, sponge devices,67 biomarkers,68 breath 
testing, and genetic testing69) have the potential to improve cost-
effectiveness and potentially expand screening to populations that 
may not have easy access to endoscopy and sedation. Specifically, 
transnasal endoscopy (as compared to traditional sedated transoral 
endoscopy) may be performed in the outpatient clinic setting with-
out sedation, leading to superior patient acceptability, safety, and 
cost-effectiveness.70 The cytosponge device consists of a spherical 
mesh compressed within a gelatinous capsule, that dissolves in the 
stomach upon being swallowed. This mesh then samples the esoph-
agus as it is withdrawn orally via string, with immunohistochemical 
staining for the Trefoil Factor 3 biomarker performed on the ob-
tained specimen. Multicenter data suggest sensitivity of 80% (higher 
for long-segment BE) and specificity of > 90% for a diagnosis of 
BE with the cytosponge device.71 
Targeted Screening for Barrett’s  
Esophagus  
Given these benefits, limitations, and costs, screening programs 
for BE among selected populations has value––the cardinal ques-
tion becomes “who” to screen and “how” to screen. 
Guidelines are concordant in recommending targeted screen-
ing when risk factors are identified (age > 50 years, male sex, 
Caucasian race, long-standing GERD, hiatal hernia, elevated body 
mass index, central obesity, smoking history, family history of BE 
or EAC)6,9 but “not” in the general asymptomatic or GERD popu-
lations (Table).72 In the absence of other risk factors, females are 
generally not targeted for screening for BE, since the risk of EAC 
in females approximates the risk of breast cancer in males.7 Since 
chronic heartburn predicts long-segment BE,2,39,73 heartburn in the 
presence of other risk factors should trigger BE screening. In this 
context, expanding screening to proven GERD with any presenting 
symptom (past evidence of erosive esophagitis, peptic stricture, or 
abnormal esophageal reflux burden)47 in patients fulfilling other risk 
categories has potential to increase the diagnostic yield of screening. 
Conclusions  
Education of clinicians––gastroenterologists as well as primary 
care providers––in recognizing GERD symptoms and risk factors 
for BE/EAC can improve screening of susceptible populations.74 
Screening should target high-risk individuals with GERD symp-
toms, but not with limited life expectancy (proposed as < 5 years)72 
or profound comorbidities. While the focus remains on typical 
reflux symptoms, clinicians should consider screening patients with 
proven GERD with risk factors for BE/EAC. New modalities un-
der investigation may decrease the costs associated with BE screen-
ing and expand access to screening. The selective use of endoscopic 
screening when risk factors for BE/EAC are identified (with ad-
equate time spent inspecting the esophagus), the use of endoscopic 
ablative therapies in dysplastic BE, and prospective outcome analy-
sis can maximize cost-effective clinical outcomes.
Take-Home Points  
•  BE represents a complication of GERD that confers an in-
creased risk for EAC.
•  Because endoscopic ablative therapies can reduce the pro-
gression of dysplastic BE to EAC, screening programs can 
impact the natural history of BE.
•  BE screening in selected at-risk populations compares favor-
ably in cost-effectiveness with other accepted cancer screen-
ing programs.
•  However, screening of the general population for BE or 
unselected patients with GERD is neither cost-effective nor 
recommended by consensus guidelines.
•  Instead, guidelines recommend targeted screening for BE in 
the presence of risk factors––including age > 50 years, male 
sex, Caucasian race, long-standing GERD, hiatal hernia, el-
evated body mass index, central obesity, smoking, and family 
history.
•  Looking forward, alternative screening tools may improve 
the cost-effectiveness of and enhance access to screening for 
BE.
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